Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1929 1
1946 1
1950 3
1951 6
1952 3
1953 1
1954 4
1955 8
1956 4
1958 5
1959 6
1960 4
1961 8
1962 4
1963 9
1964 16
1965 6
1966 14
1967 16
1968 24
1969 13
1970 23
1971 19
1972 13
1973 23
1974 18
1975 26
1976 17
1977 11
1978 21
1979 18
1980 15
1981 4
1982 4
1983 3
1984 5
1985 5
1986 7
1987 8
1988 16
1989 13
1990 13
1991 12
1992 7
1993 6
1994 5
1995 5
1996 8
1997 15
1998 22
1999 16
2000 21
2001 29
2002 47
2003 57
2004 51
2005 79
2006 83
2007 91
2008 97
2009 91
2010 105
2011 124
2012 106
2013 111
2014 150
2015 189
2016 191
2017 210
2018 242
2019 243
2020 218
2021 282
2022 283
2023 252
2024 283
2025 48

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,791 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Perez-Canedo
Page 1
Editorial Comment.
Boris RS. Boris RS. J Urol. 2021 Apr;205(4):1167-1168. doi: 10.1097/JU.0000000000001432.01. Epub 2021 Jan 25. J Urol. 2021. PMID: 33487008 No abstract available.
BORIS: a key regulator of cancer stemness.
Soltanian S, Dehghani H. Soltanian S, et al. Cancer Cell Int. 2018 Oct 5;18:154. doi: 10.1186/s12935-018-0650-8. eCollection 2018. Cancer Cell Int. 2018. PMID: 30323717 Free PMC article. Review.
BORIS (CTCFL) is a DNA binding protein which is involved in tumorigenesis. Although, there are different opinions on the level of gene expression and function of BORIS in normal and cancer tissues, the results of many studies have classified BORIS as a protei
BORIS (CTCFL) is a DNA binding protein which is involved in tumorigenesis. Although, there are different opinions on the level of gen
Reply by Authors.
Abedali ZA, Calaway AC, Large T, Lingeman JE, Mellon MJ, Boris RS. Abedali ZA, et al. J Urol. 2021 Feb;205(2):343. doi: 10.1097/JU.0000000000001419. Epub 2020 Oct 9. J Urol. 2021. PMID: 33035143 No abstract available.
Targeting CTCFL/BORIS for the immunotherapy of cancer.
Loukinov D. Loukinov D. Cancer Immunol Immunother. 2018 Dec;67(12):1955-1965. doi: 10.1007/s00262-018-2251-8. Epub 2018 Nov 2. Cancer Immunol Immunother. 2018. PMID: 30390146 Free PMC article. Review.
Recently CTCFL/BORIS has received additional attention as a target expressed in cancer stem cells (CSC). These cells drive tumor growth recurrence, metastasis, and treatment resistance. CTCFL/BORIS silencing leads to senescence and death of CSC. Therefore, an immuno …
Recently CTCFL/BORIS has received additional attention as a target expressed in cancer stem cells (CSC). These cells drive tumor grow …
CTCF and BORIS in genome regulation and cancer.
Marshall AD, Bailey CG, Rasko JE. Marshall AD, et al. Curr Opin Genet Dev. 2014 Feb;24:8-15. doi: 10.1016/j.gde.2013.10.011. Epub 2013 Dec 14. Curr Opin Genet Dev. 2014. PMID: 24657531 Review.
BORIS is aberrantly expressed frequently in cancer, leading some to propose a pro-tumourigenic role for BORIS. However, BORIS can inhibit cell proliferation, and is mutated in cancer similarly to CTCF suggesting BORIS activation in cancer may be due to
BORIS is aberrantly expressed frequently in cancer, leading some to propose a pro-tumourigenic role for BORIS. However, BOR
BORIS/CTCFL epigenetically reprograms clustered CTCF binding sites into alternative transcriptional start sites.
Pugacheva EM, Bhatt DN, Rivero-Hinojosa S, Tajmul M, Fedida L, Price E, Ji Y, Loukinov D, Strunnikov AV, Ren B, Lobanenkov VV. Pugacheva EM, et al. Genome Biol. 2024 Jan 31;25(1):40. doi: 10.1186/s13059-024-03175-0. Genome Biol. 2024. PMID: 38297316 Free PMC article.
We show that intergenic and intronic CTCF binding sites, which are transcriptionally inert in normal somatic cells, could be epigenetically reprogrammed into active de novo promoters in germ and cancer cells. BORIS/CTCFL, the testis-specific paralog of the ubiquitously exp …
We show that intergenic and intronic CTCF binding sites, which are transcriptionally inert in normal somatic cells, could be epigenetically …
BORIS in human cancers -- a review.
Martin-Kleiner I. Martin-Kleiner I. Eur J Cancer. 2012 Apr;48(6):929-35. doi: 10.1016/j.ejca.2011.09.009. Epub 2011 Oct 21. Eur J Cancer. 2012. PMID: 22019212 Review.
Re-expression of BORIS in cancers is due to the hypomethylation of its promoter. High expression of BORIS protein and RNA correlates with the tumour size and grade in cancer patients. ...BORIS antitumor vaccines have been tested in mice with several cancers, …
Re-expression of BORIS in cancers is due to the hypomethylation of its promoter. High expression of BORIS protein and RNA corr …
BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer.
Zhang Y, Fang M, Li S, Xu H, Ren J, Tu L, Zuo B, Yao W, Liang G. Zhang Y, et al. Mol Cancer. 2022 Aug 2;21(1):158. doi: 10.1186/s12943-022-01621-w. Mol Cancer. 2022. PMID: 35918747 Free PMC article.
BTApep-TAT was also used to investigate the post-translational modification (PTM) of BORIS and the role of BORIS in DNA damage repair. Site-directed mutants of BORIS were constructed and used for investigating PTM and the function of BORIS. ...CONCLUSI …
BTApep-TAT was also used to investigate the post-translational modification (PTM) of BORIS and the role of BORIS in DNA damage …
3,791 results